Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald M Jensen

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|January 4, 2012
IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?Donald M Jensen, Stanislas Pol
Antiviral Therapy|April 25, 2008
Future directions in therapy for chronic hepatitis CDonald M Jensen, Antonio Ascione
Nature Reviews. Gastroenterology & Hepatology|February 20, 2013
Future therapies for chronic hepatitis CNoura M Dabbouseh, Donald M Jensen
Liver International : Official Journal of the International Association for the Study of the Liver|December 23, 2014
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis CNicole M Welch, Donald M Jensen
Clinics in Liver Disease|April 6, 2004
Serum enzymes associated with cholestasisEva U Sotil, Donald M Jensen
Hepatology (Baltimore, Md.)|February 5, 2014
Sticker shock and the price of new therapies for hepatitis C: is it worth it?Nancy S Reau, Donald M Jensen
Infectious Disease Clinics of North America|October 23, 2012
The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virusErin T Jenkins, Donald M Jensen
Clinics in Liver Disease|February 4, 2010
Epidemiology of hepatitis B and C viruses: a global overviewHelen S Te, Donald M Jensen
Drug Design, Development and Therapy|September 20, 2019
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapyThomas G Cotter, Donald M Jensen
Hepatology (Baltimore, Md.)|February 6, 2014
Faster than a speeding bulletDonald M Jensen, Michael H Nathanson
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Liver International : Official Journal of the International Association for the Study of the Liver|January 4, 2012
IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?Donald M Jensen, Stanislas Pol
Antiviral Therapy|April 25, 2008
Future directions in therapy for chronic hepatitis CDonald M Jensen, Antonio Ascione
Nature Reviews. Gastroenterology & Hepatology|February 20, 2013
Future therapies for chronic hepatitis CNoura M Dabbouseh, Donald M Jensen
Liver International : Official Journal of the International Association for the Study of the Liver|December 23, 2014
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis CNicole M Welch, Donald M Jensen
Clinics in Liver Disease|April 6, 2004
Serum enzymes associated with cholestasisEva U Sotil, Donald M Jensen
Hepatology (Baltimore, Md.)|February 5, 2014
Sticker shock and the price of new therapies for hepatitis C: is it worth it?Nancy S Reau, Donald M Jensen
Infectious Disease Clinics of North America|October 23, 2012
The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virusErin T Jenkins, Donald M Jensen
Clinics in Liver Disease|February 4, 2010
Epidemiology of hepatitis B and C viruses: a global overviewHelen S Te, Donald M Jensen
Drug Design, Development and Therapy|September 20, 2019
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapyThomas G Cotter, Donald M Jensen
Hepatology (Baltimore, Md.)|February 6, 2014
Faster than a speeding bulletDonald M Jensen, Michael H Nathanson
Pageof 7